It’s no secret that with the generic patent cliff and a lackluster number of FDA approvals over the past few years, sales numbers across Big Pharma have been down across the board. Nobody’s happy with the numbers, and many companies are responding by banking on increased mergers and acquisitions activity, in hopes that fitting more …
August 25, 2011 By Tracy Vence Disenchanted with academic technology transfer, two business-savvy biopharma scientists set out to bridge the bench-to-business gap in two ways: by attempting to satisfy the academy’s desire for insider industry knowledge and by promoting the private sector’s interest in promising academic achievements. In 2006, graduate students Brigham Hyde and David …
By John Carroll Novartis ($NVS) CEO Joe Jimenez took a minute during a recent interview with Fortune to explain the company’s drug development strategy. Rather than go after a blockbuster indication, Novartis scientists are more focused on pathways. By pursuing a particular disease pathway with a drug designed to treat a rare disease, Novartis improves …
By John Carroll With the enthusiastic backing of NIH director Francis Collins (photo), the world’s single largest financial support of therapeutic research is throwing a chunk of its multibillion-dollar budget behind a new center designed to speed drugs from the lab to the marketplace. And Collins says that the new center for translational medicine could …
